Heparin Binding Protein

Heparin Binding Protein

Sepsis is the body’s systemic inflammatory response to infection and can progress to severe sepsis, septic shock and ultimately multiple organ failure and death. Early diagnosis and appropriate treatment of severe sepsis is vital to improve the patient’s chance of survival.

Heparin Binding Protein (HBP), also known as Cationic Antimicrobial Protein of 37kDa (CAP37) and azurocidin, is a 37kDa glycoprotein synthesised in neutrophils.

HBP is released from the secretory vesicles of activated neutrophils on contact with the endothelium. Once released, it induces a calcium-dependent rearrangement of the endothelial cell cytoskeleton, resulting in cell contraction and increased permeability of the endothelium. It is also internalised by the endothelial cells to protect them from apoptosis. HBP is also released from the secretory vesicles when M-protein/fibrinogen complexes, which are formed when M-proteins are released from bacterial cell surfaces, interact with ί2-integrins on the neutrophil cell surface. At the site of infection, HBP is also secreted from the azurophil granules during phagocytosis, where it exhibits antimicrobial activity and is responsible for the recruitment and activation of monocytes and other inflammatory mediators. It is also internalised by monocytes to prolong survival and enhance cytokine production.

HBP therefore directly contributes to the maintenance and progression of inflammation and it has been demonstrated in several major publications that measurement of HBP could be useful in identifying patients on admission to the Emergency Department who are at risk of developing sepsis with circulatory failure.

Published data also suggests that Heparin Binding Protein exhibits superior performance over existing biomarkers for the assessment of severe sepsis.




Part Number: FMHBP100

Method: ELISA

Description: 96-well microtire plate, liquid reagents, 6 calibrators, 3 controls


  • Easy-to-use ELISA technology, compatible with automated systems for higher throughput
  • Early identification of patients at risk of developing severe sepsis
  • Published data shows improved performance over existing biomarkers


Intended Use

The Axis-Shield Heparin Binding Protein (HBP) assay is an enzyme immunoassay (EIA) for the quantitative determination of Heparin Binding Protein in human plasma.


Assay Principle

The microtitre break-apart wells are coated with a monoclonal antibody to Heparin Binding Protein (HBP). During the first incubation, HBP in the sample specifically binds to the antibody-coated surface. The wells are then washed to remove unbound components. In the second incubation the Conjugate binds to any captured HBP. After further washing the bound HBP is detected by incubation with the Substrate. Addition of the Stop Solution terminates the reaction, resulting in a coloured end-product. The concentration of HBP in ng/mL is directly related to the colour generated and can be estimated by interpolation from a dose-response curve based on Calibrators.


For more information on HBP please visit www.heparinbindingprotein.com

*Products may not be approved for sale in all countries. Please contact your local distributor for further details.